ERBB2 and ovarian carcinoma: The anti-HER2 CAR-M from Klichinsky and collaborators successfully demonstrated a reduction in ovarian cancer tumor burden in mouse models and was evaluated in a first-in-human phase 1 clinical trial that focused on patients with recurrent or metastatic HER-2-overexpressing solid tumors, including ovarian cancer (NCT04660929) [79].